Loss of FBXO7 results in a Parkinson's-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway.
Stott, Simon RW
Randle, Suzanne J
Al Rawi, Sara
The Journal of pathology
John Wiley & Sons Inc.
MetadataShow full item record
Stott, S. R., Randle, S. J., Al Rawi, S., Rowicka, P., Harris, R., Mason, B., Xia, J., et al. (2019). Loss of FBXO7 results in a Parkinson's-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway.. The Journal of pathology https://doi.org/10.1002/path.5312
The field of Parkinson’s disease research has been impeded by the absence of animal models that clearly phenocopy the features of this neurodegenerative condition. Mutations in FBXO7/PARK15 are associated with both sporadic Parkinson’s disease and a severe form of autosomal recessive early-onset Parkinsonism. Here we report that conditional deletion of Fbxo7 in the midbrain dopamine neurons results in an early reduction in striatal dopamine levels, together with a slow, progressive loss of midbrain dopamine neurons and onset of locomotor defects. Unexpectedly, a later compensatory response led to a near-full restoration of dopaminergic fibre innervation in the striatum, but nigral cell loss was irreversible. Mechanistically, there was increased expression in the dopamine neurons of FBXO7-interacting protein, RPL23, which is a sensor of ribosomal stress that inhibits MDM2, the negative regulator of p53. A corresponding activated p53 transcriptional signature biased towards pro-apoptotic genes was also observed. These data suggest the neuroprotective role of FBXO7 involves its suppression of the RPL23-MDM2-p53 axis that promotes cell death in dopaminergic midbrain neurons.
Biotechnology and Biological Sciences Research Council (BB/J007846/1), DDPDgenes, Parkinson's UK and the CurePD Trust, and Wellcome Trust-MRC funded Cambridge Stem Cell Institute and an NIHR award of a Biomedical Research Centre for Addenbrooke’s Hospital/University of Cambridge.
Biotechnology and Biological Sciences Research Council (BB/J007846/1)
Royal Society (RG2010/R2)
Rosetrees Trust (A784)
Parkinson's UK (G-1701)
Embargo Lift Date
External DOI: https://doi.org/10.1002/path.5312
This record's URL: https://www.repository.cam.ac.uk/handle/1810/292689
All rights reserved